Motco Boosts Stake in Eli Lilly and Company (NYSE:LLY)

Motco increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 270.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 9,219 shares of the company's stock after acquiring an additional 6,733 shares during the period. Motco's holdings in Eli Lilly and Company were worth $5,374,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of LLY. Vanguard Group Inc. lifted its holdings in Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company's stock valued at $37,908,273,000 after purchasing an additional 659,838 shares in the last quarter. Morgan Stanley lifted its holdings in Eli Lilly and Company by 0.7% in the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company's stock valued at $6,738,605,000 after purchasing an additional 83,915 shares in the last quarter. Norges Bank acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $5,992,890,000. Northern Trust Corp lifted its stake in shares of Eli Lilly and Company by 3.6% in the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company's stock worth $5,456,314,000 after buying an additional 355,317 shares in the last quarter. Finally, International Assets Investment Management LLC boosted its position in Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company's stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

LLY has been the subject of several recent research reports. BMO Capital Markets increased their price target on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an "outperform" rating in a report on Wednesday, May 1st. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $885.00 target price (up from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday, April 30th. TheStreet raised shares of Eli Lilly and Company from a "c+" rating to a "b" rating in a research report on Friday, March 8th. Argus raised their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a "buy" rating in a research report on Tuesday, May 14th. Finally, Morgan Stanley lifted their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an "overweight" rating in a research report on Friday, February 16th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $769.53.

Eli Lilly and Company Stock Down 0.1 %

Shares of NYSE:LLY traded down $1.12 during trading on Friday, hitting $770.00. The company's stock had a trading volume of 1,670,317 shares, compared to its average volume of 2,877,174. Eli Lilly and Company has a fifty-two week low of $419.80 and a fifty-two week high of $800.78. The company has a market capitalization of $731.82 billion, a PE ratio of 113.40, a P/E/G ratio of 1.52 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The business has a 50 day moving average price of $760.66 and a two-hundred day moving average price of $686.14.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion during the quarter, compared to analysts' expectations of $8.94 billion. During the same quarter last year, the business posted $1.62 EPS. The business's quarterly revenue was up 26.0% compared to the same quarter last year. As a group, research analysts expect that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.68%. The ex-dividend date is Wednesday, May 15th. Eli Lilly and Company's dividend payout ratio is presently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.